Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: February 29, 2012
Last updated: March 7, 2012
Last verified: March 2012

RATIONALE: Studying samples of tissue from patients with rhabdoid tumors in the laboratory may help doctor learn more about changes that occur in DNA and identify genes related to cancer.

PURPOSE: This research trial studies biomarkers in samples from young patients with rhabdoid tumors.

Condition Intervention
Kidney Cancer
Genetic: DNA analysis
Genetic: fluorescence in situ hybridization
Genetic: gene expression analysis
Genetic: gene mapping
Genetic: microarray analysis
Genetic: polymerase chain reaction
Genetic: protein expression analysis
Other: laboratory biomarker analysis
Other: medical chart review

Study Type: Observational
Official Title: Endogenous DNA Transposition in Rhabdoid Tumors

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Expression and function of PGBD5 in rhabdoid tumors [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: March 2012
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Detailed Description:


  • To investigate the expression and function of PGBD5 in 50 primary rhabdoid tumors.

OUTLINE: Freshly frozen rhabdoid tumors will be studied using fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) to establish the genomic location of PGBD5. Protein expression in rhabdoid tumor tissue microarrays is also analyzed.


Ages Eligible for Study:   up to 1 Year
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Freshly frozen rhabdoid tumors from either renal or extra-renal sites from children younger than 2 years of age
  • Clinical patient information (age, gender, comorbidities, tumor stage, size, pathology, therapy, outcome) available


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01544569

Sponsors and Collaborators
Children's Oncology Group
Principal Investigator: Elizabeth A. Mullen, MD Dana-Farber Cancer Institute
  More Information

Additional Information:
No publications provided

Responsible Party: Peter C. Adamson, Children's Oncology Group - Group Chair Office Identifier: NCT01544569     History of Changes
Other Study ID Numbers: CDR0000727229, COG-AREN12B3
Study First Received: February 29, 2012
Last Updated: March 7, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
rhabdoid tumor of the kidney

Additional relevant MeSH terms:
Rhabdoid Tumor
Neoplasms by Histologic Type
Neoplasms, Complex and Mixed processed this record on April 19, 2015